Investor NewsInvestor RelationsNewsPress Releases

Premier Biomedical Appoints Carl Eller, NFL Retired Players Association President, as Marketing & Planning Vice-President

Posted at November 16, 2017 | By : | Categories : Investor News,Investor Relations,News,Press Releases | 0 Comment

El Paso, Texas, November 16, 2017Premier Biomedical, Inc. (OTCQB: “BIEI“) announced the appointment of retired NFL Pro Football Hall of Famer, Carl Eller, to the post of Marketing and Planning Vice-President.  Mr. Eller, a former defensive lineman, has spent much of his life since retiring from football working with retired NFL players and other athletes to stay healthy, both physically and mentally.  The company hopes to leverage Mr. Eller’s experience and contacts to boost the sales of their entire line of pain relief products, currently available through their website, www.painreliefmeds.com.

Mr. Eller, a six-time Pro Bowl participant who appeared in four Superbowl games with the Minnesota Vikings, is President of the NFL Retired Players Association and is focused on helping former players transition into retirement.  He is also a champion for raising awareness of Chronic Traumatic Encephalopathy (CTE), which is recognized as a growing problem in many professional, college, and even high school sports.  Mr. Eller is a licensed drug and alcohol counselor, and founded a group of substance-abuse clinics in the Twin Cities called Triumph Life Centers.  He obtained a college degree in Human Services from Metropolitan State University in 1994.

William A. Hartman, President and CEO of Premier Biomedical stated, “Mr. Eller is recognized as the driving force behind helping retired sports figures.  His goals in this area closely match the goals of Premier Biomedical Inc. – to relieve pain and suffering of people in all walks of life, both physically and emotionally.  Testimonials voluntarily provided by users of our all-natural, pesticide- and solvent-free, topical pain relief products attest to their effectiveness in relieving pain without the use of dangerous opioid pain killers.

“The company has also developed a patented combination pain medication consisting of previously approved FDA drugs most commonly used to treat chemical and alcohol addiction.  With Carl’s insights into the needs of athletes, we can guide our further product development efforts as well as provide market access to this growing segment of the population.”

For more information please contact:

William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
http://www.premierbiomedical.com/

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans.  Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent.  Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP).  The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.  The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.”  For more information please visit our website: http://www.premierbiomedical.com/

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.